secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2026-06-03T12:01:16+00:00
Accession:  0001599298-26-000049
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics authorizes affiliates and executives to purchase shares under ATM offering
--------------------------------------------------------------------------------

- Audit Committee and independent directors approved company affiliates to buy shares under existing ATM with JP Morgan.
- Co-CEOs Robert Duggan and Mahkam Zanganeh and COO/CFO Manmeet Soni indicated likely personal purchases in near term.
- No specific share numbers or formal binding commitments disclosed; purchases at prevailing bid or better.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000049/0001599298-26-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000049/smmt-20260602.htm
  HTML page:      https://secwatch.observer/filing/0001599298-26-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer